Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries has reported positive results of Copaxone (glatiramer acetate injection) which demonstrated reparative and neuroprotective effects experimental autoimmune encephalomyelitis (EAE) models.
Subscribe to our email newsletter
Copaxone helps reduce the frequency of relapses in relapsing-remitting multiple sclerosis, including patients who have experienced a first clinical episode.
During the course of the study, mice treated with Copaxone were compared with non-treated mice in relapsing-remitting and chronic multiple sclerosis (MS) disease models.
The data demonstrated remyelination, indicative of repair and a reduction of demyelination and axonal loss in mice treated with the drug candidate.
In addition to remyelination and neuronal preservation, the central nervous system of mice treated with Copaxone had smaller lesions, increased axonal density and a higher prevalence of normal appearing axons, the research concluded.